EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System

Adam Goldman iD, Emanuel Raschi, Amit Druyan, Kassem Sharif iD, Adi Lahat, Ilan Ben-Zvi, Shomron Ben-Horin

United European Gastroenterology Journal · 2025-05 · 13 (4) · 566-575

DOI: 10.1002/ueg2.12736 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 30.12.2024. Verfasst von Adam Goldman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel. Hauptthemen laut MEDLINE: Intestinal Perforation, Janus Kinase Inhibitors, Adverse Drug Reaction Reporting Systems, Arthritis, Rheumatoid. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastrointestinal perforations have been reported in a small number of rheumatoid arthritis (RA) patients treated with Janus kinase (JAK) inhibitors in clinical trials. However, large‐scale postmarketing data repositories are needed to further investigate this potentially rare but serious adverse event.

Methods

A retrospective, pharmacovigilance study of the FDA adverse event reporting system (July 2014 to September 2023) assessing the reporting of gastrointestinal perforations following JAK inhibitors compared to biological disease‐modifying antirheumatic drugs (bDMARDs) in RA patients. The adjusted reporting odds ratio (adj.ROR) was calculated using a multivariable logistic regression model.

Results

Of 399,983 RA patients included in the study, 76,446 were treated with JAK inhibitors (tofacitinib, n = 52,365; upadacitinib, n = 21,856; baricitinib, n = 2225) and 323,537 were treated with bDMARDs (TNF inhibitors, rituximab, and abatacept). Overall, 230 cases of gastrointestinal perforation following JAK inhibitors were identified, with a median time of 9 (IQR: 4–22) months from treatment initiation. Compared with bDMARDs, JAK inhibitors were associated with a higher‐than‐expected reporting of gastrointestinal perforations (adj.ROR = 1.98[1.69−2.31]). Increased reporting of gastrointestinal perforations was observed among recipients of JAK inhibitors or bDMARDs who used steroids or non‐steroidal anti‐inflammatory drugs concurrently (adj.ROR = 2.82 [2.41–3.31]). Perforations of both the upper and lower gastrointestinal tract were significantly over‐reported ( n = 51, adj.ROR = 1.55 [1.12–2.14], n = 143, adj.ROR = 1.78 [1.46–2.17], respectively). Furthermore, the safety signal was significant across all JAK inhibitors: tofacitinib ( n = 125, adj.ROR = 1.52 [1.25–1.85]), upadacitinib ( n = 84, adj.ROR = 2.73 [2.17–3.44]), and baricitinib ( n = 21, adj.ROR = 5.38 [3.46–8.37]).

Conclusion

In this global pharmacovigilance study, all JAK inhibitors were associated with increased reporting of gastrointestinal perforations compared with bDMARDs in RA patients. Until more data on IBD patients emerge, careful surveillance and increased clinicians' awareness should also be advocated for this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal PerforationJanus Kinase InhibitorsAdverse Drug Reaction Reporting SystemsArthritis, RheumatoidAntirheumatic AgentsHumansFemaleMaleUnited StatesRetrospective StudiesMiddle AgedUnited States Food and Drug AdministrationPharmacovigilancePyrazolesPurinesAgedPyrimidinesAzetidinesSulfonamidesHeterocyclic Compounds, 3-RingPiperidinesAdult

Stichwörter der Autor:innen

JAKiadverse eventsanti‐JAKautoimmune diseasesbaricitinibcomplicationspharmacovigilancerheumatoid arthritistofacitinibupadacitinib

Substanzen

Janus Kinase InhibitorsPyrazolesPurinesAntirheumatic AgentsPyrimidinesAzetidinesSulfonamidestofacitinibbaricitinibupadacitinib

Autor:innen und Institutionen

  • Department of Internal Medicine, Sheba Medical Center, Ramat-Gan, Israel.
  • Department of Epidemiology and Preventive Medicine, School of Public Health, School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • The Sheba Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel.
  • Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
  • School of Medicine, Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Department of Gastroenterology, Sheba Medical Center, Ramat-Gan, Israel.

ORCID-Profile: Adam Goldman, Kassem Sharif

Zitieren

APA

Goldman, A., Raschi, E., Druyan, A., Sharif, K., Lahat, A., Ben-Zvi, I., & Ben-Horin, S. (2025). Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System. United European Gastroenterology Journal, 13(4), 566-575. https://doi.org/10.1002/ueg2.12736

Vancouver

Goldman A, Raschi E, Druyan A, Sharif K, Lahat A, Ben-Zvi I, et al. Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System. United European Gastroenterology Journal. 2025;13(4):566-575. doi:10.1002/ueg2.12736

BibTeX
@article{Goldman2025,
  author = {Goldman, Adam and Raschi, Emanuel and Druyan, Amit and Sharif, Kassem and Lahat, Adi and Ben-Zvi, Ilan and Ben-Horin, Shomron},
  title = {Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {566--575},
  doi = {10.1002/ueg2.12736}
}
Kostenlos starten →